Iceland· IS-EU/1/20/1526/002
Tukysa
A tucatinib product containing tucatinibum inn, registered in Iceland by Pfizer Europe MA EEIG*. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Tucatinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EH03 (tucatinib), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 9 of them publish a price we can compare per daily dose
Tucatinib · ATC L01EH03
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tucatinib costs, country by country.
Normalised to the WHO defined daily dose (0.6 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tucatinib · price per daily dose (0.6 g)
USD · FX 28 Sept 2026
- FR France$3.96
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Tucatinibum INN
- Manufacturer
- Pfizer Europe MA EEIG*
- Country
- Iceland (IS)
- ATC code
- L01EH03
- ATC class
- Tucatinib
- Defined daily dose
- 0.6 g, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean39770284 stk x1 þpakkiISK 1002333
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
309 interactions on record for tucatinib.
Graded by severity as the source publishes them — 126 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Tucatinib · interactions on record
309 records
- 126 severe
- 173 moderate
- 10 minor
Most severe, free to view
- CisaprideA03FA02severe
- NaloxegolA06AH03severe
- BudesonideA07EA06severe
- EliglustatA16AX10severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Tucatinib in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumTukysa 150 mgPfizer Europe MA
- SwitzerlandTukysa 150 mg, FilmtablettenPfizer AG
- CzechiaTUKYSAPfizer Europe MA EEIG, Bruxelles
- SpainTUKYSA 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULAPfizer Europe Ma Eeig
- FinlandTUKYSAPfizer Europe MA EEIG
- FranceTUKYSA 150 mg, comprimé pelliculéPFIZER EUROPE MA EEIG (BELGIQUE)
- IrelandTUKYSA 150 mg film-coated tabletsPfizer Europe MA EEIG
- NetherlandsTukysa 150 mg, filmomhulde tabletPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Tukysa
- Norway · Tukysa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7bfb78e1-edb3-405e-993d-5b74ddf86219 GET /v1/drugs/7bfb78e1-edb3-405e-993d-5b74ddf86219?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "L01EH03",
"marketed": true,
"strength": "150 mg",
"ma_number": "EU/1/20/1526/002",
"substance": "Tucatinibum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í krabbameinslækningum.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "44238"
}See everything about tucatinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.